RA Capital Management 13F holdings, Q3 2018
Holdings as of September 30, 2018 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 26 US equity positions worth $1.9bn in its Q3 2018 13F filing. The largest position was WVE at 20.1% of the reported book, followed by ASND and SLDB. Against the Q2 2018 filing, it opened 3 new positions, added to 6 and reduced 1 among the top 26 holdings.
What did RA Capital Management own in Q3 2018? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2018 |
|---|---|---|---|---|---|---|---|
| 1 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 20.1% | $375.6m | 7,512,049 | 0% | held |
| 2 | ASND ASCENDIS PHARMA A S | Healthcare | 16.1% | $300.5m | 4,240,536 | 0% | held |
| 3 | SLDB SOLID BIOSCIENCES INC | 6.8% | $126.9m | 2,689,444 | 0% | held | |
| 4 | ENDOCYTE INC | 5.9% | $110.0m | 6,196,143 | 10% | added | |
| 5 | ZOGENIX INC | 5.0% | $93.2m | 1,878,768 | 64% | added | |
| 6 | MYOVANT SCIENCES LTD | 4.9% | $91.6m | 3,451,859 | 22% | added | |
| 7 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 3.8% | $70.5m | 9,234,692 | 32% | added |
| 8 | RA PHARMACEUTICALS INC | 3.7% | $69.7m | 3,851,808 | 0% | held | |
| 9 | INFLARX NV | 3.6% | $67.5m | 1,967,848 | 0% | held | |
| 10 | IMMU IMMUNOMEDICS INC | 3.5% | $65.0m | 3,119,778 | 0% | held | |
| 11 | DICERNA PHARMACEUTICALS INC | 3.2% | $60.0m | 3,933,489 | 0% | held | |
| 12 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.0% | $56.9m | 1,950,332 | 27% | added |
| 13 | ARVN ARVINAS INC | Healthcare | 2.8% | $52.9m | 3,138,412 | – | new |
| 14 | SG7 SAGE THERAPEUTICS INC | 2.7% | $49.6m | 350,933 | 0% | held | |
| 15 | CRINETICS PHARMACEUTICALS INC | 2.6% | $48.7m | 1,701,017 | – | new | |
| 16 | TGTX TG THERAPEUTICS INC | Healthcare | 2.5% | $45.9m | 8,198,337 | 92% | added |
| 17 | MNTA MOMENTA PHARMACEUTICALS INC | 2.2% | $41.0m | 1,558,357 | -58% | reduced | |
| 18 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.7% | $31.9m | 1,441,070 | 0% | held | |
| 19 | EIDOS THERAPEUTICS INC | 1.2% | $21.6m | 2,162,671 | 0% | held | |
| 20 | KALA PHARMACEUTICALS INC | 1.1% | $20.9m | 2,113,236 | 0% | held | |
| 21 | PROGENICS PHARMACEUTICALS INC | 1.0% | $19.0m | 3,030,303 | – | new | |
| 22 | SCPHARMACEUTICALS INC | 0.9% | $16.8m | 2,857,143 | 0% | held | |
| 23 | APELLIS PHARMACEUTICALS INC | 0.9% | $16.0m | 900,000 | 0% | held | |
| 24 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 0.7% | $12.6m | 1,121,153 | 0% | held |
| 25 | GLYCOMIMETICS INC | 0.2% | $3.7m | 253,547 | 0% | held | |
| 26 | PROTEON THERAPEUTICS INC | 0.1% | $2.6m | 1,337,462 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.